Precision Bone Disease Platform

Targeted skeletal therapeutics for rare disease, fractures and debilitating bone disorders

Bone Health Concerns Cost 30 Billion Annually in the US Alone

Effecting over 18 Million and ranging from fractures to debilitating bone diseases, bone health has far reaching consequences impacting an individual’s ability to perform the most essential functions of day to day life

Treatments as specific as a bone injury or disease

Effecting over 18 Million and ranging from fractures to debilitating bone diseases, bone health has far reaching consequences impacting an individual’s ability to perform the most essential functions of day to day life

LEARN MORE

Fractures & Spinal fusion

Our platform is aimed and lowering the negative impact on the 22M and 500K patients who experience fractures and Spinal fusion incidents annually in the US.

LEARN MORE

Rare Bone Disease

Osteogenesis Imperfecta is the first of four rare bone diseases we are targeting in our early development pipeline.

LEARN MORE

NOV004

Development Timeline

A phase 1 SAD study will address Safety, Tolerability and PK questions that will lead to P1b MAD study where we will expand our inquiry into issues surrounding dosing and efficacy in subjects with bone fractures.

study
2021
2022
COMPLETED
Q1-Q2

CMC - DS/DP

P1b MAD

P1 SAD

Q2-Q4